IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How?
- PMID: 34228779
- DOI: 10.1001/jama.2021.11121
IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How?
Comment on
-
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330. JAMA. 2021. PMID: 34228774 Free PMC article.
Similar articles
-
Immunotherapy in COVID-19: why, who, and when?Lancet Respir Med. 2021 Jun;9(6):549-551. doi: 10.1016/S2213-2600(21)00232-0. Epub 2021 May 18. Lancet Respir Med. 2021. PMID: 34015326 Free PMC article. No abstract available.
-
Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.Transpl Infect Dis. 2020 Aug;22(4):e13326. doi: 10.1111/tid.13326. Epub 2020 Jun 5. Transpl Infect Dis. 2020. PMID: 32406985 Free PMC article. No abstract available.
-
IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).J Biol Regul Homeost Agents. 2020 Sep-Oct,;34(5):1623-1627. doi: 10.23812/20-34-4EDIT-65. J Biol Regul Homeost Agents. 2020. PMID: 32744052
-
Monoclonal antibody therapy in COVID-19.J Biol Regul Homeost Agents. 2021 Mar-Apr;35(2):423-427. doi: 10.23812/Conti_Edit_35_2_1. J Biol Regul Homeost Agents. 2021. PMID: 33904269
-
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context.Lancet Respir Med. 2021 Jun;9(6):655-664. doi: 10.1016/S2213-2600(21)00139-9. Epub 2021 Apr 27. Lancet Respir Med. 2021. PMID: 33930329 Free PMC article. Review.
Cited by
-
Ofeleein i mi Vlaptin-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.Medicina (Kaunas). 2022 Feb 17;58(2):309. doi: 10.3390/medicina58020309. Medicina (Kaunas). 2022. PMID: 35208631 Free PMC article. Review.
-
Receptor-binding domain-anchored peptides block binding of severe acute respiratory syndrome coronavirus 2 spike proteins with cell surface angiotensin-converting enzyme 2.Front Microbiol. 2022 Sep 13;13:910343. doi: 10.3389/fmicb.2022.910343. eCollection 2022. Front Microbiol. 2022. PMID: 36177466 Free PMC article.
-
Pathophysiological mechanisms of thrombosis in acute and long COVID-19.Front Immunol. 2022 Nov 16;13:992384. doi: 10.3389/fimmu.2022.992384. eCollection 2022. Front Immunol. 2022. PMID: 36466841 Free PMC article. Review.
-
The Impact of Tocilizumab on Radiological Changes Assessed by Quantitative Chest CT in Severe COVID-19 Patients.J Clin Med. 2022 Feb 25;11(5):1247. doi: 10.3390/jcm11051247. J Clin Med. 2022. PMID: 35268338 Free PMC article.
-
Inflawell® improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial.Inflammopharmacology. 2022 Apr;30(2):465-475. doi: 10.1007/s10787-022-00928-w. Epub 2022 Feb 24. Inflammopharmacology. 2022. PMID: 35201518 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical